Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Taletrectinib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : AnHeart Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Nippon Kayaku will be responsible for regulatory approvals and commercialization of AB-106 (taletrectinib) for ROS1-positive NSCLC in Japan, and will have rights to further develop taletrectinib for new indications in th...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $40.0 million
October 30, 2023
Lead Product(s) : Taletrectinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : AnHeart Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Darinaparsin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Solasia Pharma KK
Deal Size : Inapplicable
Deal Type : Inapplicable
Solasia Announces Launch of Darvias® in Japan
Details : DARVIAS® (darinaparsin), an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors.
Product Name : Darvias
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : Darinaparsin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Solasia Pharma KK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darinaparsin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Solasia Pharma KK
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the license agreement, Solasia and Nippon Kayaku will make further efforts to provide a new treatment option to patient suffering from PTCL and for marketing rights to darinaparsin.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
October 26, 2021
Lead Product(s) : Darinaparsin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Solasia Pharma KK
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Celltrion
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 13, 2014
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Celltrion
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase III Study of NK105 in Patients With Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 19, 2012
Lead Product(s) : Apaziquone
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : HANDOK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2011
Lead Product(s) : Apaziquone
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : HANDOK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2010
Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2010
Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gusperimus
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2010
Lead Product(s) : Gusperimus
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
